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RESEARCH ARTICLE Open Access
Shared care follow-up of patients with B-
cell neoplasms based on nurse-led
telephone consultations and PRO-data: a
feasibility study from the North Denmark
Region
Mia Sommer1,2,3,4* , Lone Frandsen1, Paw Jensen1,4, Søren Ramme Nielsen1, Lars Børty Nielsen1,
Rasmus Froberg Brøndum1,2,4, Martin Bøgsted1,2,4, Jakob Madsen1, Marianne Tang Severinsen1,4,
Erik Elgaard Sørensen2,3, Mette Grønkjær2,3 and Tarec Christoffer El-Galaly1,2,4
Abstract
Background: Patients with B-cell neoplasms in remission are monitored with regular physician visits at the hospital.
The current standard follow-up procedure is not evidence-based or individualized to patient needs. To improve and
individualize the follow-up, we investigated the feasibility of a shared care follow-up initiative, with alternating
physician visits and nurse-led telephone consultations and assessments based on patient-reported outcome (PRO)
data.
Methods: Patients ≥18 years diagnosed with B-cell neoplasms were eligible for the study when they were in
remission and stable without treatment for at least 6 months. Patients were assigned to alternating visits with
physicians and nurse-led telephone consultations. The nurse-led telephone consultations were based on PROs,
which were collected with the European Organization for Research and Treatment of Cancer questionnaire (EORTC-
QLQ-C30), the Myeloproliferative Neoplasm – Symptom Assessment Form, and the Hospital Anxiety and Depression
Scale. Patients completed questionnaires before every nurse-led consultation. We also applied the Patient Feedback
Form to survey patient acceptance of the requirement of questionnaire completion. We applied descriptive
statistics, in terms of counts (n) and proportions (%), to describe the study population and all endpoints.
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Results: Between February 2017 and December 2018, 80 patients were enrolled. Adherence, measured as the recruitment
rate, was 96% (80/83), and the drop-out rate was 6% (5/80). During the study period, 3/80 (4%) patients relapsed, and 5/80
(6%) patients returned to the standard follow-up, because they required closer medical observation. Relapses were
diagnosed based on unscheduled visits requested by patients (n = 2) and patient-reported symptoms reviewed by the nurse
(n = 1). The response rate to questionnaires was 98% (335/341). A total of 58/79 (74%) patients completed the Patient
Feedback Form; 51/57 (89%) patients reported improved communication with health care professionals; and 50/57 (88%)
patients reported improved recollection of symptoms as a result of completing questionnaires.
Conclusion: Based on patient adherence, a low relapse rate, and positive patient attitudes towards completing
questionnaires, we concluded that a shared care follow-up, supported by PROs, was a feasible alternative to the standard
follow-up for patients with B-cell disease in remission.
Keywords: Hematologic neoplasms, Feasibility study, Supportive care, Patient-reported outcome measures, Nurse-led
telephone consultations
Background
B-cell neoplasms include diseases, such as non-Hodgkin
lymphoma, Hodgkin lymphoma, multiple myeloma, and
chronic lymphoblastic leukemia (CLL) [1]. These dis-
eases originate in the lymphatic system, and relevant
treatments include chemotherapy, with or without im-
munotherapy, stem cell transplantation, and novel tar-
geted therapies [1–3]. Patients with incurable B-cell
neoplasms that do not require immediate, active treat-
ment are sometimes managed with watch and wait
(WAW) follow-ups. These patients, and patients in re-
mission after treatment are routinely followed by the at-
tending physician. Clinical guidelines exist for assessing
survivors of hematological cancer during follow-up, but
the guidelines are inconsistent [1–3]. The follow-up
interval and the total post-treatment follow-up time for
patients with B-cell neoplasms depend on the specific
diagnosis and whether the patient has curable, aggressive
lymphoma or chronic, incurable B-cell malignancies,
such as indolent lymphoma or CLL. The follow-up strat-
egy can also be influenced by the choice of therapy and
the response to treatment; for example, patients at high
risk of relapse are closely monitored, due to the potential
for suboptimal response to treatment [4]. In Denmark,
patients with CLL or indolent lymphoma that are man-
aged with WAW are followed at the outpatient clinic
every 4–12 months, and the frequency depends on a
number of clinical parameters [5–7]. For example, when
patients with diffuse large B-cell lymphoma (DLBCL) re-
spond to a curative intent treatment with complete re-
mission and have a low risk of relapse, they are followed
every 3–4months in the first year after treatment and
every 6 months in the following 2 years; after that,
follow-up is terminated. In contrast, patients with a high
risk of relapse are typically followed at the outpatient
clinic with regular visits for up to 5 years. Similar sched-
ules are applied to patients that receive palliative therapy
for incurable B-cell malignancies, but as a rule, follow-
ups are lifelong for this group [3]. Post-treatment
follow-ups are mainly focused on symptom assessment
and physical examinations for signs of recurrent disease
[4, 8]. Patient-reported symptoms are the single most
important factors for early detection of recurrent lymph-
oma, as shown in a previous study, where patient-
reported symptoms preceded confirmation of lymphoma
relapse in 64% of patients [9]. Follow-up strategies for B-
cell neoplasms are based on expert consensus and obser-
vational studies, due to the absence of supporting evi-
dence from controlled clinical trials [5–7, 10]. Many
patients experience frequent, non-specific symptoms,
treatment-related complications, and other health-
related issues associated with cancer survivorship [11–
14]. For example, many cancer survivors experience sig-
nificant fatigue, neuropathy, and anxiety related to a fear
of recurrence [15, 16]; all of these symptoms can have a
negative impact on the quality of life [13]. Furthermore,
the literature has demonstrated that these patients have
reported unmet needs, in particular, emotional and in-
formational needs [17–19]. In recent years, nurse-led in-
terventions have proven successful, in terms of meeting
patient needs and addressing psychosocial issues. Add-
itionally, these interventions have demonstrated high pa-
tient acceptance and offered advantages, including
convenience and individualized care [20–22]. Studies
have indicated that PROs can be successfully imple-
mented during the follow-up of patients with cancer;
PROs have led to improved patient-provider communi-
cation, patient satisfaction, and early relapse detection
[23–26]. Moreover, implementing PROs in clinical prac-
tice could also support patients in taking an active part
in follow-ups and identifying specific health complaints
relevant to the individual patient [27, 28]. Hence, com-
bining nurse-led interventions and collecting PROs on
cancer survivorship for patients with hematological can-
cer might contribute to providing patient-centered care
and increase the quality of care. This approach has not
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been sufficiently explored in a hematological setting.
Therefore, we investigated the feasibility of a shared care
follow-up initiative, with alternating standard physician
visits and nurse-led telephone consultations, based on
the PROs of patients with B-cell neoplasms.
Methods
Study design
This study was designed as a feasibility study. It was
conducted from February 2017 to June 2019. Patient re-
cruitment ended in June 2018, and data collection was
set to end in December 2018.
Study location
The study was conducted at the Department of
Hematology, Aalborg University Hospital, Denmark. Over
the past decade, the number of new patients admitted to
this hospital has increased yearly. In 2019, the outpatient
clinic served approximately 4000 patients with all varieties
of hematological diagnoses, at all stages of the disease tra-
jectory (diagnostics, treatment, and follow-up). Among
these patients, approximately 1500 (37.5%) were diag-
nosed with B-cell neoplasms.
Study population
Eligible participants included all patients with B-cell
neoplasms that were placed under observation in WAW
mode or were previously treated and were currently in
post-treatment follow-up. The patients were enrolled by
their attending physician at a scheduled in-hospital
follow-up visit. The sample size was reached by conveni-
ence sampling, and as many eligible patients as possible
were included during the recruitment period [29]. All
patients provided written signed consent before entering
the study.
Study criteria
Inclusion criteria were: age ≥ 18 years; a diagnosis of B-
cell neoplasm (CLL and lymphomas); disease in remis-
sion or stable without treatment for at least 6 months
prior to inclusion; sufficient self-care to report new
symptoms; and a willingness to return questionnaires on
a regular basis. In this context, and based on the WHO’s
definition of the concept, self-care was defined as the
ability of an individual patient to seek hospital care when
necessary [30]. Exclusion criteria were: medical condi-
tions, such as severe comorbidities that required close
medical attention; conditions that impaired the patient’s
ability to understand and comprehend the study concept
(e.g., dementia); and an inability to complete the ques-
tionnaires online.
Follow-up structure
The nurse-led telephone consultations replaced every
other visit with the physician. At the end of every sched-
uled physician visit, two future consultations were
booked, which included one nurse-led telephone con-
sultation and a subsequent in-hospital physician visit.
The nurse-led telephone consultations were scheduled
ad hoc, and the total number of consultations for each
patient was determined by the attending physician, based
on the individual follow-up interval and the patient’s
diagnosis, risk profile, age, and prior treatment. The
physician visits were conducted by the three hematolo-
gists that participated in the study. The telephone con-
sulting nurse had 15 years of clinical hematology
experience.
The patients completed questionnaires at inclusion and
prior to every nurse-led consultation. Patients were also
asked to complete the questionnaires prior to physician
visits, to monitor health-related quality of life (HRQoL)
and symptom burden over time; however, physicians were
not obliged to review the responses. Patients accessed the
questionnaires from an email-alert with a link to an online
healthcare platform (Dansk Telemedicin A/S, Denmark).
The email-alert was sent 1 week prior to each scheduled
nurse-led telephone consultation; when no response was
received to the initial email-alert, a reminder was sent
after 3 days. The nurse reviewed responses to the individ-
ual questions and the overall scores, which were calculated
based on questionnaire-specific standard calculations [31–
33]. Based on the questionnaire responses, the nurse
assessed any development or abnormal response and dis-
cussed solutions and health-promoting options with the
patient during the following telephone conversation.
When any health issues were reported that might have
been related to the B-cell neoplasm, or when other signifi-
cant health issues emerged, an in-hospital nurse consult-
ation could be arranged the subsequent day. Alternatively,
the patient could be offered a physician consultation at
the earliest available time slot. Prior to all types of consul-
tations, routine blood tests were assessed by the
physicians.
PRO instruments
PRO data were collected with three instruments: the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC-QLQ-
C30), the Myeloproliferative Neoplasm – Symptom As-
sessment Form (MPN-SAF), and the Hospital Anxiety and
Depression Scale (HADS) [34–36]. EORTC-QLQ-C30
was a 30-item instrument that included an overall Global
Health Status domain, five functional domains (physical,
emotional, cognitive, social, and role functioning), and
nine symptom domains (fatigue, nausea and vomiting,
pain, dyspnea, insomnia, appetite loss, constipation,
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diarrhea, and financial difficulties). Each domain was
scored from 0 to 100, and higher scores indicated better
HRQoL, better functioning, or a worse symptom burden
[37]. MPN-SAF was a 17-item disease-specific symptom
questionnaire developed for patients with myeloprolifera-
tive diseases [35]. This instrument provided sufficiently
generic questions on symptoms relevant to B-cell malig-
nancies; however, no lymphoma-specific questionnaires
were available in the local language at the time the study
started. Therefore, we added four ad hoc questions to
MPN-SAF to ensure that typical B-cell neoplasm symp-
toms were covered adequately. The ad hoc questions are
presented in Table 1. HADS [36] was a 14-item question-
naire designed to assess anxiety and depression symptoms
in patients with somatic diseases. HADS included two
scales, one for anxiety (HADS–A) and one for depression
(HADS–D), to differentiate the two states. Formal licenses
for EORTC-QLQ-C30 and HADS were obtained prior to
study start [38, 39]. No formal license was required for
MPN-SAF, however, written consent for the use of the
questionnaire was obtained from the developer [32].
Patient acceptance
We assessed how well patients accepted the task of com-
pleting questionnaires as part of follow-up in a cross-
sectional survey, conducted between November 2018
and March 2019. Patients were sent an email invitation
to participate via the REDCap survey tool [40] . Data
were collected with the Patient Feedback Form (PFF), a
generic questionnaire that included 13 items for evaluat-
ing the applicability and value of PROs in clinical prac-
tice. PFF has been translated into Danish and validated
by Tolstrup et. al. [41] and written consent to use the
questionnaire was obtained from the authors [41]. All
participants, including patients that had dropped out of
the study for various reasons, were invited to complete
the survey. This survey was conducted anonymously to
limit a potential response bias and to avoid an overesti-
mation of patient acceptance [42].
Statistical analyses
The endpoints were patient inclusion, the questionnaire
response rate, the drop-out rate, and patient acceptance
of completing questionnaires as a part of the follow-up.
We performed descriptive statistics, expressed as the
counts (n) and proportions (%).
Results
Patient adherence
Eighty-three patients were invited to participate in the
study. The patient inclusion process is illustrated in
Fig. 1. Among these, 80 patients agreed to participate;
thus, the recruitment rate was 96% (80/83). Among the
80 included patients (median age 68 years, range 28–82);
42/80 (53%) were men and 38/80 (48%) were women.
The most frequent B-cell neoplasms were follicular
lymphoma (FL; n = 29), CLL (n = 17), and DLBCL (n =
14). Relevant characteristics of the study population are
shown in Table 2. During the study period, 341 ques-
tionnaires were distributed. Of these, 335 were com-
pleted and returned, which resulted in a response rate of
98% (335/341).
During follow-up, 5/80 (6%) patients dropped out of
the study due to excessive questions asked (n = 1), im-
paired eyesight, which led to difficulties reading the
questionnaires (n = 1), and a preference for regular hos-
pital follow-ups (n = 3). Another 8/80 (10%) patients
dropped out of the study due to medical reasons. Of
these, 3/80 (4%) patients experienced a relapse of the B-
cell neoplasm. Two relapses (DLBCL) were diagnosed at
unscheduled visits requested by the patients, due to the
symptoms experienced. The other relapse (MZL) was
detected when patient-reported symptoms were
reviewed by the study nurse prior to the nurse consult-
ation. Finally, 5/80 (6%) patients were excluded because
closer medical observation was needed due to mental
problems (n = 1), infections unrelated to B-cell neoplasia
activity (n = 2), suspicion of relapsed disease raised by an
enlarged lymph node, which required regular manual as-
sessments (n = 1), and terminal illness, due to another
cancer (n = 1).
Nurse-led telephone consultations
During the study period, 129 nurse-led telephone consul-
tations were conducted (median 1 consultations/patient,
range 1–4) and the median time spent in a nurse consult-
ation was 12min (range 3–67min). Forty-six patients 46/
80 (58%) were followed with one or more nurse-led tele-
phone consultations without further action, and 34/80
(43%) patients had blood test results or a symptom burden
that required discussion with the physician. Five patients
5/34 (15%) were scheduled for an in-hospital appointment
with their attending physician after a discussion between
the nurse and the attending physician. Twenty-two
Table 1 Ad hoc questions added to MPN-SAF to cover B-cell
neoplasm-specific symptoms associated with recurrent disease
in a shared care follow-up initiative
Have you since last consultation:
Noticed swollen lymph nodes? Yes: No:
Had infections that demanded antibiotic
treatment?
Yes: No:
Experienced the same symptoms as
last time you were ill from your blood
disease?
0 (No) 1 2 3 4 5 6 7 8 9 10
(Yes)
Do you feel ill from your blood disease? 0 (No) 1 2 3 4 5 6 7 8 9 10
(Yes)
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patients 22/80 (28%) were advised to seek help from their
general practitioner, due to health complaints that were
determined to be unrelated to B-cell neoplasia (e.g., dys-
pnea, urinary issues, musculoskeletal pain). No patients
were scheduled for a nurse visit at the outpatient clinic. In
total, 124/129 (96%) nurse-led telephone consultations re-
placed a visit to the hospital, compared to the standard
follow-up procedure.
Patient acceptance
We conducted a patient acceptance survey to assess atti-
tudes towards completing questionnaires as part of the
follow-up. One patient died prior to the survey start,
hence 79/80 (99%) patients were invited to participate.
Among these, 58/79 (74%) patients agreed to participate,
including 24/56 (43%) women and 32/56 (57%) men (2
patients did not provide gender information). The pa-
tient feedback suggested that patients had an overall
positive attitude towards completing questionnaires as
part of the follow-up. The results from the patient ac-
ceptance survey are presented in Table 3.
Discussion
This study investigated the feasibility of a shared care
follow-up initiative, featuring alternating nurse-led tele-
phone consultations, supported by PROs, and regular
physician visits, as an alternative to the standard follow-
up for patients treated for B-cell neoplasms. In this study,
we found a high recruitment rate of 96% (80/83) and a
high questionnaire response rate of 98% (335/341).
Saltbæk et al., tested the feasibility of a nurse-led
follow-up among survivors of breast cancer. They re-
ported a recruitment rate of 78% and a questionnaire re-
sponse rate of 95.3% [43]. Furthermore, Beaver et al.,
tested the feasibility of nurse-led telephone consultations
in survivors of prostate cancer. They reported a recruit-
ment rate of 75% [44]. Hence, our findings were consist-
ent with previous feasibility studies of nurse-led
telephone consultations. In fact, our recruitment and
questionnaire response rates were higher than those re-
ported in earlier studies. These results suggest that nurse-
led telephone consultations supported by PROs are feas-
ible among survivors of B-cell cancer. During the study
period, five patients withdrew from our study, due to vari-
ous reasons, which led to a drop-out rate of 6% (5/80).
Similarly, Saltbæk et al.,and Beaver et a.l, reported drop-
out rates of 4 and 6.5%, respectively [43, 44], consistent
with our findings. These results suggest that survivors of
hematological cancer could adhere well to a follow-up
model that included nurse-led telephone consultations
and PROs. The patients that withdrew from the study
varied in age, gender, and diagnosis, which suggested that
dropping-out was not driven by specific characteristics.
Additionally, only 3/80 (4%) patients relapsed during the
study period, which was a low relapse rate in the selected
population. Interestingly, two relapses were discovered by
patients. One had clear symptoms that were reported in
the questionnaires underscoring the ineffectiveness of
Fig. 1 Flowchart of the patient inclusion process
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routine follow-up in detection of relapse in patients with
low risk of relapse. This is consistent with the findings in
a recent Danish study showing that patient reported
symptoms prereceded relapse detection in the majority of
the patients with DLBCL [45]. In total, 10/80 (10%) pa-
tients left the study during the study period due to re-
lapse, a need for closer observation or as a consequence
of the patients’ choice. Thus, despite targeting patients
with high degree of self-care and low risk of relapse,
follow-up should be a dynamic process and allow patients
to shift between follow-up strategies according to prefer-
ences at a given time.
The patients’ feedback suggest that most patients
found it easier to recall relevant symptoms and found
that the conversations with health professionals im-
proved having returned questionnaires. This finding was
consistent with those of Greenhalgh et al., who showed
that PROs in clinical practice could help support
patient-provider communications and patient care. The
authors concluded that completing PROs could poten-
tially change the way patients reflected on their health
condition [26]. Indeed, we found that, overall, patient ac-
ceptance was positive. Although our findings on patient
acceptance might not directly reflect the feasibility of the
initiative, the patient acceptance did reflect patient per-
spectives on completing questionnaires as a part of clin-
ical practice.
Our findings on the feasibility of nurse-led tele-
phone consultations were consistent with similar ini-
tiatives, which also showed that nurse-led telephone
consultations were feasible, efficient, and well-
accepted by patients [20–22, 46]. Most previous stud-
ies focused on patients with solid tumors, such as
breast, prostate, and/or lung cancer. However, one
previous study investigated the feasibility of nurse-led
telephone follow-up for patients with indolent and
chronic hematological malignancies [47]. Another
study tested a model for following-up patients that
survived lymphoma [48]. The present study has added
evidence to existing studies with our findings that a
high recruitment rate and high response rate gave rise
to the positive patient adherence in patients that sur-
vived hematological cancer. Furthermore, we pre-
sented a follow-up model that was based on nurse-led
telephone consultations, but with the added require-
ment that PROs were actively used as a tool for the
detection of present health concerns. The systematic
use of PROs as preparation for the nurse-led tele-
phone consultations made it possible to provide
problem-based consultations and address specific pa-
tient concerns at an appropriate time. In addition, the
PROs served to prepare the patients for their upcom-
ing consultations, in terms of their awareness of new
or persistent symptoms. Consequently, the active, sys-
tematic use of PROs prior to any patient contact ap-
peared to be valuable in clinical practice. However,
the potential value of the use of PROs should be con-
sidered in light of the fact that this joint initiative in-
cluded both the option to rearrange the follow-up
and the addition of PROs; hence, we should not draw
conclusions on these components separately. How-
ever, the patient feedback suggested that PROs could
be valuable, both in clinical practice and in a shared
care follow-up initiative, because they enhanced pa-
tient reflection on their present symptoms, patient-
provider communications, and patient involvement.
Table 2 Baseline demographics, treatment, and follow-up
characteristics of patients with B-cell neoplasms included in a
shared care follow-up initiative
Characteristic Total
N 80
Female 38
Male 42
Age, y; median 68
Age range, y 28–82
Diagnosis
FL 29
DLBCL 14
CLL 17
MZL 10
WM 5
LPL 3
MCL 1
HL 1
Number of visits to a physician, median (range) 1 (0–4)
Number of nurse consultations, median (range) 1 (0–4)
Time since diagnosis, y; median (range) 4.4 (1.1–20.2)
Time since last treatment, y; median (range) 3.4 (1.3–16.3)
Follow-up interval, months
2–3 34
4–5 25
6 21
Number of treatment lines
1 48
2 4
> 2 4
No previous treatment (watch and wait) 24
FL Follicular Lymphoma, DLBCL Diffuse Large B-Cell Lymphoma, CLL Chronic
Lymphocytic Leukemia, MZL Marginal Zone Lymphoma, WM Waldenstrom
Macroglobulinemia, LPL Lymphoblastic Lymphoma, Mantle Cell Lymphoma, HL
Hodgkin Lymphoma
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Although we found that this follow-up model was
feasible, and we observed positive patient adherence, the
study was conducted without a control group. Therefore,
we could not conclude whether this initiative improved
the quality of care or patient satisfaction over the stand-
ard follow-up.
It has been demonstrated that some patients de-
clined participation in telehealth interventions, be-
cause they felt unsure about using technology or they
had concerns about privacy [49, 50]. This suggested
that a large number of declined invitations to partici-
pate could contribute to an overestimation of the
feasibility of the intervention. In the present study, we
did not determine the reasons for declining participa-
tion. Although this is important knowledge, only
three patients declined participation after receiving
detailed information about the study by the study
nurse. This low decline rate suggested that the con-
cerns of those patients did not significantly influence
our estimation of study feasibility.
In this study, the patients were selected by their at-
tending physicians, which might have contributed to that
the patients’ refrained from declining participation.
However, in order to limit potential influence from the
physician – patient relationship, strong emphasis was
placed on the fact that participation was voluntary and
that the patients could return to in-hospital follow-up
without any consequences for future treatment and care.
The sample size was achieved by convenience sam-
pling [29, 51]; we included as many patients possible
during the study period. The shared care follow-up ini-
tiative was offered as an optional service for interested
patients, and it did not plan to include patients that felt
more secure with in-hospital visits. However, conveni-
ence sampling poses the risk of a selection bias. The
main assumption of this sampling method is that the
target population is homogeneous, compared to random
sampling methods [29, 51]. Consequently, our sample
might have been too homogeneous to generalize results
to other patient populations. However, by including 80
patients, we attempted to increase the likelihood of in-
cluding a heterogeneous study population [52]. Indeed,
some heterogeneity was achieved, based on the age
range of the included patients and the range of disease
types. However, the size of the study population was in-
sufficient to provide powered, meaningful subgroup
Table 3 Patient Feedback Form results on patient acceptance of completing questionnaires as part of a shared care follow-up
initiative for patients treated for B-cell neoplasms
Questions Number of
respondents
Responses, N (%)
Too short Just
right
Too
long
The lengths of the questionnaires were 58 0 (0) 47 (81) 11 (19)
Not often
enough
Just
right
Too
often
The number of times I was asked to complete the questionnaires was 58 0 (0) 53 (91) 5 (9)
Strongly
agree
Agree Disagree Strongly
Disagree
It was easy to complete the questionnaires 58 15 (26) 36 (62) 7 (12) 0 (0)
It made sense to complete the questionnaires 58 16 (28) 36 (62) 5 (9) 1 (2)
It was easy to understand the questions 58 18 (31) 36 (62) 4 (7) 0 (0)
Completing the questionnaires made it easier for me to remember my
symptoms and side effects, when I spoke with the healthcare professionals
57 15 (26) 35 (61) 7 (12) 0 (0)
Completing the questionnaires improved the conversation with the health care
professionals
57 14 (25) 37 (65) 6 (11) 0 (0)
The health care professionals used the information from the questionnaires in
connection with my treatment
54 15 (28) 30 (56) 9 (17) 0 (0)
It is my experience that the quality of my treatment was improved due to the
fact that I had completed the questionnaires
54 9 (17) 35 (65) 10 (19) 0 (0)
It is my experience that the communication with the health care professionals
was improved due to the fact that I had completed the questionnaires
55 9 (16) 35 (64) 11 (20) 0 (0)
Completing the questionnaires made me feel involved in my treatment 56 18 (32) 30 (54) 8 (14) 0 (0)
I would recommend that other patients should complete the questionnaires 56 23 (41) 32 (57) 1 (2) 0 (0)
I would like to continue completing questionnaires in the future 54 24 (44) 24 (44) 4 (7) 2 (4)
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analyses of individual diagnostic categories or age
groups. Furthermore, the limited drop-out rate did not
allow an exploration of the features associated with the
likelihood of completing the study.
Conclusion
To provide evidence for revising the standard follow-up
procedure, we tested the feasibility of a shared care
follow-up initiative, supported by PROs, for patients
with B-cell neoplasms. We found good patient adher-
ence, in terms of a high recruitment rate, a high re-
sponse rate, and a low drop-out rate. Furthermore,
relapse detection did not seem to be compromised. Pa-
tient feedback suggested that patients had an overall
positive attitude towards completing questionnaires as
part of the follow-up. In conclusion, a shared care
follow-up initiative supported by PROs for patients with
B-cell neoplasms in remission appeared to be feasible
and acceptable as an alternative to standard practice for
a patient population with a perceived high level of self-
care and low risk of relapse. The inclusion of PROs in
the post-treatment follow-up was a valuable addition, in
terms of increasing reflection on the patient’s own
health, enhancing patient-provider communications, and
encouraging patient involvement. Although further re-
search is warranted, including an exploration of patient
experiences, based on our results, the systematic use of
PROs could potentially offer a more individualized,
problem-based approach to nurse-led consultations and
provide support for more meaningful, relevant physician
consultations. Future studies should explore the cost ef-
fectiveness of this proposed model of shared care follow-
up. In addition, other aspects of PRO use should be eval-
uated in the follow-up of patients with B-cell neoplasms,
such as the potential for promoting early detection of re-
lapse or progressive disease in a more high-risk
population.
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